Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/06/22
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/04/22
Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateAccesswire • 08/04/22
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022Accesswire • 07/28/22
Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 05/18/22
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment ConferenceAccesswire • 05/18/22
After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS)Zacks Investment Research • 05/16/22
Pieris Pharmaceuticals, Inc (PIRS) CEO Stephen S. Yoder on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateAccesswire • 05/11/22
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022Accesswire • 05/04/22
Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/01/22
Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate UpdateAccesswire • 03/01/22
Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022Accesswire • 02/23/22
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp AlfaAccesswire • 01/14/22
Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402Accesswire • 01/03/22